Procaine is a DNA-demethylating agent with growth-inhibitory effects in human cancer cells.

Methylation-associated silencing of tumor suppressor genes is recognized as being a molecular hallmark of human cancer. Unlike genetic alterations, changes in DNA methylation are potentially reversible. This possibility has attracted considerable attention from a therapeutics standpoint. Nucleoside-analogue inhibitors of DNA methyltransferases, such as 5-aza-2'-deoxycytidine, are able to demethylate DNA and restore silenced gene expression. Unfortunately, the clinical utility of these compounds has not yet been fully realized, mainly because of their side effects. A few non-nucleoside inhibitors of DNA methyltransferases have been reported, including the anti-arrhythmia drug procainamide. Following this need to find new demethylating agents, we have tested the potential use of procaine, an anesthetic drug related to procainamide. Using the MCF-7 breast cancer cell line, we have found that procaine is a DNA-demethylating agent that produces a 40% reduction in 5-methylcytosine DNA content as determined by high-performance capillary electrophoresis or total DNA enzyme digestion. Procaine can also demethylate densely hypermethylated CpG islands, such as those located in the promoter region of the RAR beta 2 gene, restoring gene expression of epigenetically silenced genes. This property may be explained by our finding that procaine binds to CpG-enriched DNA. Finally, procaine also has growth-inhibitory effects in these cancer cells, causing mitotic arrest. Thus, procaine is a promising candidate agent for future cancer therapies based on epigenetics.

[1]  J. Herman,et al.  A gene hypermethylation profile of human cancer. , 2001, Cancer research.

[2]  R. Jaenisch,et al.  Mutagenicity of 5-aza-2'-deoxycytidine is mediated by the mammalian DNA methyltransferase. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[3]  B. Richardson,et al.  Procainamide inhibits DNA methyltransferase in a human T cell line. , 1991, The Journal of rheumatology.

[4]  M. Esteller.  CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future , 2002, Oncogene.

[5]  J. Herman,et al.  p14ARF silencing by promoter hypermethylation mediates abnormal intracellular localization of MDM2. , 2001, Cancer research.

[6]  R. Momparler,et al.  Antineoplastic action of 5-aza-2′-deoxycytidine and histone deacetylase inhibitor and their effect on the expression of retinoic acid receptor β and estrogen receptor α genes in breast carcinoma cells , 2001, Cancer Chemotherapy and Pharmacology.

[7]  S. Piantadosi,et al.  Advances in Brief Reversal of GSTP 1 CpG Island Hypermethylation and Reactivation of-Class Glutathione S-Transferase ( GSTP 1 ) Expression in Human Prostate Cancer Cells by Treatment with Procainamide 1 , 2001 .

[8]  L. B. Diego,et al.  High‐performance capillary electrophoretic method for the quantification of 5‐methyl 2'‐deoxycytidine in genomic DNA: Application to plant, animal and human cancer tissues , 2002, Electrophoresis.

[9]  S. Hanash,et al.  Hydralazine and procainamide inhibit T cell DNA methylation and induce autoreactivity. , 1988, Journal of immunology.

[10]  W. Koopman,et al.  Lupus-inducing drugs alter the structure of supercoiled circular DNA domains. , 1990, Arthritis and rheumatism.

[11]  J. Herman,et al.  A systematic profile of DNA methylation in human cancer cell lines. , 2003, Cancer research.

[12]  T. Yau,et al.  Local anaesthetics as hypoxic radiosensitizers, oxic radioprotectors and potentiators of hyperthermic killing in mammalian cells. , 1980, The British journal of radiology.

[13]  R. Chlebowski,et al.  Doxorubicin cytotoxicity enhanced by local anesthetics in a human melanoma cell line. , 1982, Cancer treatment reports.

[14]  S. Sukumar,et al.  Evidence of epigenetic changes affecting the chromatin state of the retinoic acid receptor β2 promoter in breast cancer cells , 2000, Oncogene.

[15]  Peter A. Jones,et al.  The fundamental role of epigenetic events in cancer , 2002, Nature Reviews Genetics.

[16]  J. Herman,et al.  DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. , 2001, Human molecular genetics.

[17]  S. Mizuno,et al.  Selective enhancement of the cytotoxicity of the bleomycin derivative, peplomycin, by local anesthetics alone and combined with hyperthermia. , 1982, Cancer research.

[18]  J. Herman,et al.  Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[19]  Bert Vogelstein,et al.  DNMT1 and DNMT3b cooperate to silence genes in human cancer cells , 2002, Nature.

[20]  T. Thomas,et al.  Effects of lupus-inducing drugs on the B to Z transition of synthetic DNA. , 1986, Arthritis and rheumatism.

[21]  M. Caligiuri,et al.  Aberrant CpG-island methylation has non-random and tumour-type–specific patterns , 2000, Nature Genetics.

[22]  P. Jones,et al.  Effects of 5-azacytidine and its 2'-deoxyderivative on cell differentiation and DNA methylation. , 1985, Pharmacology & therapeutics.

[23]  J. Minna,et al.  Promoter methylation and silencing of the retinoic acid receptor-beta gene in lung carcinomas. , 2001, Journal of the National Cancer Institute.

[24]  I. Oohara,et al.  Spectroscopic studies on histone-DNA interactions. I. The interaction of histone (H2A, H2B) dimer with DNA: DNA sequence dependence. , 1987, Journal of molecular biology.

[25]  Manel Esteller,et al.  Hypermethylation-associated Inactivation of the Cellular Retinol-Binding-Protein 1 Gene in Human Cancer. , 2002, Cancer research.

[26]  J. Herman,et al.  Analysis of adenomatous polyposis coli promoter hypermethylation in human cancer. , 2000, Cancer research.

[27]  I. Oohara,et al.  Spectroscopic studies on histone-DNA interactions. II. Three transitions in nucleosomes resolved by salt-titration. , 1987, Journal of molecular biology.

[28]  M. Fraga,et al.  The transcription factor Slug represses E-cadherin expression and induces epithelial to mesenchymal transitions: a comparison with Snail and E47 repressors , 2003, Journal of Cell Science.

[29]  Esteban Ballestar,et al.  The affinity of different MBD proteins for a specific methylated locus depends on their intrinsic binding properties. , 2003, Nucleic acids research.

[30]  J. Herman,et al.  Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer , 1999, Nature Genetics.

[31]  Javier Benitez,et al.  Cancer Epigenetics and Methylation , 2002, Science.

[32]  M. Widschwendter,et al.  Methylation and silencing of the retinoic acid receptor-beta2 gene in breast cancer. , 2000, Journal of the National Cancer Institute.

[33]  Y. Kuppumbatti,et al.  Methylation of conserved CpG sites neighboring the beta retinoic acid response element may mediate retinoic acid receptor beta gene silencing in MCF-7 breast cancer cells , 2000, Oncogene.

[34]  J. Herman,et al.  Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. , 1998, Proceedings of the National Academy of Sciences of the United States of America.